Cited by 522Global Cancer Incidence and ScreeningProstate Cancer Diagnosis and TreatmentProstate Cancer Treatment and Research

The DOI matches its Crossref record; 26 of the 28 references it cites were found in a registry or an index.

Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries

Wong, Martin C.S., Goggins, William B., Wang, Harry H.X., Fung, Franklin D.H., Leung, Colette, Wong, Samuel Y.S., Ng, Chi Fai, Sung, Joseph J.Y.·2016·European Urology

DOI 10.1016/j.eururo.2016.05.043

Open this paper in CoChat — free account

Abstract

BACKGROUND: Prostate cancer (PCa) is a leading cause of mortality and morbidity globally, but its specific geographic patterns and temporal trends are under-researched. OBJECTIVE: To test the hypotheses that PCa incidence is higher and PCa mortality is lower in countries with higher socioeconomic development, and that temporal trends for PCa incidence have increased while mortality has decreased over time. DESIGN, SETTING, AND PARTICIPANTS: Data on age-standardized incidence and mortality rates in 2012 were retrieved from the GLOBOCAN database. Temporal patterns were assessed for 36 countries using data obtained from Cancer incidence in five continents volumes I-X and the World Health Organization mortality database. Correlations between incidence or mortality rates and socioeconomic indicators (human development index [HDI] and gross domestic product [GDP]) were evaluated. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The average annual percent change in PCa incidence and mortality in the most recent 10 yr according to join-point regression. RESULTS AND LIMITATIONS: Reported PCa incidence rates varied more than 25-fold worldwide in 2012, with the highest incidence rates observed in Micronesia/Polynesia, the USA, and European countries. Mortality rates paralleled the incidence rates except for Africa, where PCa mortality rates were the highest. Countries with higher HDI (r=0.58) and per capita GDP (r=0.62) reported greater incidence rates. According to the most recent 10-yr temporal data available, most countries experienced increases in incidence, with sharp rises in incidence rates in Asia and Northern and Western Europe. A substantial reduction in mortality rates was reported in most countries, except in some Asian countries and Eastern Europe, where mortality increased. Data in regional registries could be underestimated. CONCLUSIONS: PCa incidence has increased while PCa mortality has decreased in most countries. The reported incidence was higher in countries with higher socioeconomic development. PATIENT SUMMARY: The incidence of prostate cancer has shown high variations geographically and over time, with smaller variations in mortality.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2016.05.043

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
Global patterns and trends in colorectal cancer incidence and mortality
Arnold, M., Sierra, M. S., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2016) · Gut · doi:10.1136/gutjnl-2015-310912 · Cited by 5,392
The United Nations Development Programme
Oestreich, J. E. (2017) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780190637347.003.0003 · Cited by 4,875
Cancer Epidemiology and Prevention
Schottenfeld, D. (2006) · doi:10.1093/acprof:oso/9780195149616.001.0001 · Cited by 3,376
Counting the dead and what they died from: an assessment of the global status of cause of death data.
(2005) · Europe PMC (PubMed Central) · Cited by 1,975
GLOBOCAN 2008 v1.2, Cancer incidence and mortality world-wide : IARC Cancer Base No. 10
Ferlay, J. (2010) · Medical Entomology and Zoology · Cited by 1,636
International Variation in Prostate Cancer Incidence and Mortality Rates
Center, M. M., Jemal, A., Lortet-Tieulent, J., Ward, E., Ferlay, J., Brawley, O., & Bray, F. (2012) · European Urology · doi:10.1016/j.eururo.2012.02.054 · Cited by 1,521
Estimating average annual per cent change in trend analysis
Clegg, L. X., Hankey, B. F., Tiwari, R. C., Feuer, E. J., & Edwards, B. K. (2009) · Statistics in Medicine · doi:10.1002/sim.3733 · Cited by 1,271
International Variation in Female Breast Cancer Incidence and Mortality Rates
Desantis, C. E., Bray, F., Ferlay, J., Lortet‐Tieulent, J., Anderson, B. O., & Jemal, A. (2015) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0535 · Cited by 829

Show all 28 references

Sorted by citations

Items 101–200 of 522

Patient-derived, three-dimensional spheroid cultures provide a versatile translational model for the study of organ-confined prostate cancer
Linxweiler, J., Hammer, M., Muhs, S., Kohn, M., Pryalukhin, A. E., Veith, C., Bohle, R. M., Stöckle, M., Junker, K., & Saar, M. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2803-5 · Cited by 36
Personalization of prostate cancer therapy through phosphoproteomics
Yang, W., Freeman, M. R., & Kyprianou, N. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0014-0 · Cited by 36
Gut microbiota in patients with prostate cancer: a systematic review and meta-analysis
Huang, H., Liu, Y., Zhi, W., Chen, C., Wang, C., Li, H., & Yang, X. (2024) · BMC Cancer · doi:10.1186/s12885-024-12018-x · Cited by 39
Comparison of cancer incidence and mortality in three GDP per capita levels in China, 2013
Yang, Z., Zheng, R., Zhang, S., Zeng, H., Xia, C., Li, H., Wang, L., Wang, Y., & Chen, W. (2017) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2017.05.02 · Cited by 33
Retrospective Analysis of Patients With Prostate Cancer Initiating GnRH Agonists/Antagonists Therapy Using a German Claims Database: Epidemiological and Patient Outcomes
Hupe, M. C., Hammerer, P. G., Ketz, M., Kossack, N., Colling, C., & Merseburger, A. S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00543 · Cited by 33
Vesicourethral Anastomotic Stenosis After Open or Robot-assisted Laparoscopic Retropubic Prostatectomy—Results from the Laparoscopic Prostatectomy Robot Open Trial
Modig, K. K., Godtman, R. A., Bjartell, A. S., Carlsson, S., Haglind, E., Hugosson, J., Månsson, M., Steineck, G., Thorsteinsdóttir, T., Tyritzis, S. Ι., et al. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.10.012 · Cited by 33
Vinculin and filamin-C are two potential prognostic biomarkers and therapeutic targets for prostate cancer cell migration
Ai, J., Jin, T., Yang, L., Wei, Q., Yang, Y., Li, H., & Zhu, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.19397 · Cited by 33
Multifunctional antioxidant nanoliposome‐mediated delivery of PTEN plasmids restore the expression of tumor suppressor protein and induce apoptosis in prostate cancer cells
Singh, S., Asal, R., & Bhagat, S. (2018) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36510 · Cited by 32
Characterization of the prognostic values and response to immunotherapy/chemotherapy of Krüppel‐like factors in prostate cancer
Meng, J., Lu, X., Zhou, Y., Zhang, M., Gao, L., Gao, S., Yan, F., & Liang, C. Y. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15242 · Cited by 32
A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA–Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer
Tolmeijer, S. H., Boerrigter, E., Schalken, J. A., Geerlings, M. J., van Oort, I. M., van Erp, N. P., Gerritsen, W. R., Ligtenberg, M. J. L., & Mehra, N. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00084 · Cited by 32
CDC20 and PTTG1 are Important Biomarkers and Potential Therapeutic Targets for Metastatic Prostate Cancer
Dai, L., Song, Z., Wei, D., Zhang, J., Liang, J., Wang, B.-B., Ma, W.-T., Li, L., Dang, Y.-L., Zhao, L., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01729-3 · Cited by 32
Cancer incidence and mortality and risk factors in member countries of the " Belt and Road " initiative
Wang, B., He, F., Hu, Y., Wang, Q., Wang, D., Sha, Y., & Wu, J. (2022) · BMC Cancer · doi:10.1186/s12885-022-09657-3 · Cited by 33
The role of masculinities in psychological and emotional help seeking by men with prostate cancer
Goodwin, B. C., Ralph, N., Ireland, M. J., Hyde, M. K., Oliffe, J. L., Dunn, J., & Chambers, S. (2020) · Psycho-Oncology · doi:10.1002/pon.5264 · Cited by 32
Vitamin D levels and the risk of prostate cancer and prostate cancer mortality
Stroomberg, H. V., Vojdeman, F. J., Madsen, C. M., Helgstrand, J. T., Schwarz, P., Heegaard, A., Olsen, A., Tjønneland, A. M., Lind, B., Brasso, K., et al. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1837391 · Cited by 31
Qualitative and Quantitative Reporting of a Unique Biparametric MRI: Towards Biparametric MRI‐Based Nomograms for Prediction of Prostate Biopsy Outcome in Men With a Clinical Suspicion of Prostate Cancer (IMPROD and MULTI‐IMPROD Trials)
Perez, I. M., Jambor, I., Kauko, T., Verho, J., Ettala, O. O., Falagario, U. G., Merisaari, H., Kiviniemi, A., Taimen, P., Syvänen, K. T., et al. (2019) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26975 · Cited by 30
Prediction of biochemical recurrence in prostate cancer patients who underwent prostatectomy using routine clinical prostate multiparametric MRI and decipher genomic score
Jambor, I., Falagario, U. G., Ratnani, P., Perez, I. M., Demir, K., Merisaari, H., Sobótka, S., Haines, G. K., Martini, A., Beksac, A. T., et al. (2019) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26928 · Cited by 29
YB-1: The key to personalised prostate cancer management?
Bates, M., Boland, A. J., McDermott, N., & Marignol, L. H. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.006 · Cited by 29
Elevated MRE11 expression associated with progression and poor outcome in prostate cancer
Wang, J., Xu, W., Yu, W., Zhu, Y., Qin, X.-J., Zhang, H., & Ye, D. (2019) · Journal of Cancer · doi:10.7150/jca.31454 · Cited by 29
Long non‐coding RNA LINC00673 silencing inhibits proliferation and drug resistance of prostate cancer cells via decreasing KLF4 promoter methylation
Jiang, Z., Zhang, Y., Chen, X., Wu, P., & Chen, D. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14883 · Cited by 29
FSH Is Responsible for Androgen Deprivation Therapy–Associated Atherosclerosis in Mice by Exaggerating Endothelial Inflammation and Monocyte Adhesion
Wang, Q., Han, J., Liang, Z., Geng, X., Du, Y., Zhou, J., Yao, W., & Xu, T. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319426 · Cited by 28
Racial disparities in prostate cancer in the UK and the USA: similarities, differences and steps forwards
Dee, E. C., Todd, R., Ng, K., Aidoo-Micah, G., Amen, T. B., Moon, Z., Vince, R., Muralidhar, V., Mutsvangwa, K., Funston, G., et al. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00948-x · Cited by 28
Preliminary results of a 68Ga‐PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision‐making
Rousseau, C., Thiec, M. L., Ferrer, L., Rusu, D., Rauscher, A., Maucherat, B., Frindel, M., Baumgartner, P., Fleury, V., Denis, A., et al. (2019) · The Prostate · doi:10.1002/pros.23869 · Cited by 29
Clinico-Radiological Characteristic-Based Machine Learning in Reducing Unnecessary Prostate Biopsies of PI-RADS 3 Lesions with Dual Validation
Kan, Y., Zhang, Q., Hao, J., Wang, W., Zhuang, J., Gao, J., Huang, H., Liang, J., Marra, G., Calleris, G., et al. (2019) · European Radiology · doi:10.1007/s00330-020-06958-8 · Cited by 28
Design and Validation of a Nonparasitic 2R1T Parallel Hand-Held Prostate Biopsy Robot With Remote Center of Motion
Jiang, W., Wu, D., Dong, W., Ding, J., Ye, Z., Zeng, P., & Gao, Y. (2023) · Journal of Mechanisms and Robotics · doi:10.1115/1.4062793 · Cited by 28
Clinical association of metabolic syndrome, C‐reactive protein and testosterone levels with clinically significant prostate cancer
Gómez‐Gómez, E., Carrasco‐Valiente, J., Campos-Hernández, J. P., Blanca, A., Jiménez‐Vacas, J. M., Ruiz-García, J., Valero-Rosa, J., Luque, R. M., & Requena-Tapia, M. J. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13994 · Cited by 28
Shear-wave elastography: role in clinically significant prostate cancer with false-negative magnetic resonance imaging
Xiang, L., Fang, Y., Wan, J., Xu, G., Yao, M., Ding, S.-S., Liu, H., & WU, R. T. (2019) · European Radiology · doi:10.1007/s00330-019-06274-w · Cited by 28
Silencing of ELK3 Induces S‐M Phase Arrest and Apoptosis and Upregulates SERPINE1 Expression Reducing Migration in Prostate Cancer Cells
Mao, Y., Li, W., Hua, B., Gu, X., Pan, W., Chen, Q., Xu, B., Wang, Z., & Lu, C. (2020) · BioMed Research International · doi:10.1155/2020/2406159 · Cited by 28
Assessment of harms, benefits, and cost‐effectiveness of prostate cancer screening: A micro‐simulation study of 230 scenarios
Getaneh, A. M., Heijnsdijk, E. A. M., Roobol, M. J., & de Koning, H. J. (2020) · Cancer Medicine · doi:10.1002/cam4.3395 · Cited by 27
Data science for healthcare predictive analytics
Leung, C. K.-S., Fung, D. L. X., Mushtaq, S. B., Leduchowski, O. T., Luc, B. R., Jin, H., Cuzzocrea, A., & Zhang, C. Y. (2020) · International Database Engineering and Applications Symposium (IDEAS) · doi:10.1145/3410566.3410598 · Cited by 27
Self-citation
Prostate cancer epigenetics — from pathophysiology to clinical application
Constâncio, V., Lobo, J., Sequeira, J. P., Henrique, R., & Jerónimo, C. (2025) · Nature Reviews Urology · doi:10.1038/s41585-024-00991-8 · Cited by 26
Integrating machine learning driven virtual screening and molecular dynamics simulations to identify potential inhibitors targeting PARP1 against prostate cancer
Aldakheel, F. M., Alduraywish, S. A., & Dabwan, K. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-97208-8 · Cited by 27
Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines
Jorda, R., Řezníčková, E., Kiełczewska, U., Maj, J., Morzycki, J. W., Siergiejczyk, L., Bazgier, V., Berka, K., Rárová, L., & Wojtkielewicz, A. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.040 · Cited by 26
Evaluating liquid biopsies for methylomic profiling of prostate cancer
Silva, R., Moran, B., Russell, N. M., Fahey, C., Vlajnic, T., Manecksha, R. P., Finn, S. P., Brennan, D. J., Gallagher, W. M., & Perry, A. S. (2020) · Epigenetics · doi:10.1080/15592294.2020.1712876 · Cited by 24
HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method
Sharifi, N., Salmaninejad, A., Ferdosi, S., Bajestani, A. N., Khaleghiyan, M., Estiar, M. A., Jamali, M., Nowroozi, M. R., & Shakoori, A. (2016) · Oncology Letters · doi:10.3892/ol.2016.5235 · Cited by 26
A novel mouse model of human prostate cancer to study intraprostatic tumor growth and the development of lymph node metastases
Linxweiler, J., Körbel, C., Müller, A., Hammer, M., Veith, C., Bohle, R. M., Stöckle, M., Junker, K., Menger, M. D., & Saar, M. (2018) · The Prostate · doi:10.1002/pros.23508 · Cited by 26
Do men with lower urinary tract symptoms have an increased risk of advanced prostate cancer?
Jákupsstovu, J. Ø. Í., & Brodersen, J. (2018) · BMJ · doi:10.1136/bmj.k1202 · Cited by 26
Trends of Prostate Cancer Morbidity in Low-Incidence Countries from 1990–2019
Jiang, J., Chen, B., Tang, B., Yang, J., Zhang, T., Li, J., Tan, D., & Wei, Q. (2024) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-23-1034 · Cited by 25
The global, regional, and national prostate cancer burden and trends from 1990 to 2021, results from the global burden of disease study 2021
Liu, X., & Jiang, H. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1553747 · Cited by 24
Neutravidin biosensor for direct capture of dual-functional biotin-molecular beacon-AuNP probe for sensitive voltammetric detection of microRNA
Fredj, Z., Azzouzi, S., Turner, A. P. F., Ali, M. B., & Mak, W. C. (2017) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2017.03.160 · Cited by 24
Sleep disorders associated with risk of prostate cancer: a population-based cohort study
Chung, W., & Lin, C. (2019) · BMC Cancer · doi:10.1186/s12885-019-5361-6 · Cited by 24
Increasing incidence of prostate cancer in Taiwan
Lin, P., Chang, S.-W., Tsai, L.-H., Kan, H.-C., Liu, J., Chuang, C., Pang, S., & Yu, K. (2020) · Medicine · doi:10.1097/md.0000000000022336 · Cited by 24
Yin Yang 1 promotes the neuroendocrine differentiation of prostate cancer cells via the non‐canonical WNT pathway (FYN/STAT3)
Liu, R., Xu, Z., Huang, X., Xu, B., & Chen, M. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1422 · Cited by 24
Efficacy and safety of periprostatic nerve block combined with perineal subcutaneous anaesthesia and intrarectal lidocaine gel in transrectal ultrasound guided transperineal prostate biopsy: A Prospective Randomised Controlled Trial
Lv, Z., Jiang, H., Hu, X., Yang, C., Chand, H., Tang, C., & Li, Y. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0155-0 · Cited by 24
Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis
Afshar‐Oromieh, A., Vollnberg, B., Alberts, I., Bähler, A., Sachpekidis, C., Dijkstra, L., Haupt, F., Boxler, S., Gross, T., Holland‐Letz, T., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04438-w · Cited by 24
Drug-Drug Interactions in Prostate Cancer Treatment
Hebenstreit, D., Pichler, R., & Heidegger, I. M. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.05.016 · Cited by 23
The tumor suppressor miR-642a-5p targets Wilms Tumor 1 gene and cell-cycle progression in prostate cancer
Beveridge, D. J., Richardson, K. L., Epis, M. R., Brown, R. A. M., Stuart, L. M., Woo, A. J., & Leedman, P. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-97190-x · Cited by 21
PSCA regulates IL‐6 expression through p38/NF‐κB signaling in prostate cancer
Liu, L., Li, E., Luo, L., Zhao, S., Li, F., Wang, J., Luo, J., & Zhao, Z. (2017) · The Prostate · doi:10.1002/pros.23399 · Cited by 23
Simultaneous targeting of AMPK and mTOR is a novel therapeutic strategy against prostate cancer
Zhao, G., Forn‐Cuní, G., Scheers, M., Lindenbergh, P. P., Yin, J., van Loosen, Q. C., Passarini, L., Chen, L., & Snaar-Jagalska, E. B. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216657 · Cited by 23
Knowledge of prostate cancer and screening practices among men in Sokoto, Nigeria
Awosan, K. J., Yunusa, E. U., Agwu, N. P., & Taofiq, S. (2018) · Asian Journal of Medical Sciences · doi:10.3126/ajms.v9i6.20751 · Cited by 22
LncRNA NR2F2-AS1 positively regulates CDK4 to promote cancer cell proliferation in prostate carcinoma
Fu, X., Wang, D., Shu, T., Cui, D., & Fu, Q. (2019) · The Aging Male · doi:10.1080/13685538.2019.1670157 · Cited by 22
Clinicopathological signature of p21-activated kinase 1 in prostate cancer and its regulation of proliferation and autophagy via the mTOR signaling pathway
Wang, Z., Jia, G., Li, Y., Liu, J., Luo, J., Zhang, J., Xu, G., & Chen, G. (2017) · Oncotarget · doi:10.18632/oncotarget.15124 · Cited by 22
Azole-Pyrimidine Hybrid Anticancer Agents: A Review of Molecular Structure, Structure Activity Relationship, and Molecular Docking
Eze, C. C., Ezeokonkwo, M. A., Ugwu, D. I., Eze, F. U., Onyeyilim, E. L., Attah, S. I., & Okonkwo, V. I. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220318090147 · Cited by 21
Machine learning-based prediction model and visual interpretation for prostate cancer
Chen, G., Dai, X., Zhang, M., Tian, Z., Jin, X., Mei, K., Huang, H., & Wu, Z. (2023) · BMC Urology · doi:10.1186/s12894-023-01316-4 · Cited by 21
Identification of aberrantly methylated differentially expressed genes in prostate carcinoma using integrated bioinformatics
Wu, K., Yin, X., Jin, Y., Liu, F., & Gao, J. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0763-8 · Cited by 21
Prognostic Value of Genes and Immune Infiltration in Prostate Tumor Microenvironment
Sun, W., Shi, H., Yuan, Z., Li, X., Xiang, X., Quan, X., Shi, W., & Jiang, L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.584055 · Cited by 20
Mechanistic insights into genetic susceptibility to prostate cancer
Tian, P. W., Zhong, M., & Wei, G. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.09.025 · Cited by 22
Clinical Biofluid Assays for Prostate Cancer
Borbiev, T., Kohaar, I., & Petrovics, G. (2023) · Cancers · doi:10.3390/cancers16010165 · Cited by 20
68Ga‐PSMA‐11 PET‐CT study in prostate cancer patients with biochemical recurrence and non‐contributive 18F‐Choline PET‐CT: Impact on therapeutic decision‐making and biomarker changes
Barbaud, M., Frindel, M., Ferrer, L., Thiec, M. L., Rusu, D., Rauscher, A., Maucherat, B., Baumgartner, P., Fleury, V., Colombié, M., et al. (2018) · The Prostate · doi:10.1002/pros.23751 · Cited by 20
PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer
Zhai, L., Fan, Y., Sun, S.-S., Wang, H., Meng, Y., Hu, S., Wang, X., Yu, W., & Jin, J. (2018) · Scandinavian Journal of Urology · doi:10.1080/21681805.2018.1545799 · Cited by 20
Self-citation
Gene Polymorphism-related Individual and Interracial Differences in the Outcomes of Androgen Deprivation Therapy for Prostate Cancer
Fujimoto, N., Shiota, M., Tomisaki, I., & Minato, A. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.01.006 · Cited by 20
Auxiliary Medical Decision System for Prostate Cancer Based on Ensemble Method
Wu, J., Zhuang, Q., & Tan, Y. (2020) · Computational and Mathematical Methods in Medicine · doi:10.1155/2020/6509596 · Cited by 19
MicroRNA-199b-3p suppresses malignant proliferation by targeting Phospholipase Cε and correlated with poor prognosis in prostate cancer
Liu, J., Quan, Z., Gao, Y., Wu, X., & Zheng, Y. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.08.078 · Cited by 19
The Impact of Lifestyle on Prostate Cancer: A Road to the Discovery of New Biomarkers
Leitão, C., Matos, B., Roque, F., Herdeiro, M. T., & Fardilha, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102925 · Cited by 20
With increasing trends of prostate cancer in the Saudi Arabia and Arab World: Should we start screening programs?
Arafa, M. A., & Rabah, D. M. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i6.447 · Cited by 19
Prognostic implication and functional annotations of Rad50 expression in patients with prostate cancer
Xu, W., Wang, J., Sheng, H., Qu, Y., Wang, H., Zhu, Y., Shi, G., Zhang, H., & Ye, D. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29580 · Cited by 19
Self-citation
Towards the differential diagnosis of prostate cancer by the pre-treatment of human urine using ionic liquids
Pereira, M. M., Calixto, J. D., Sousa, A. C. A., Pereira, B. J., Lima, Á. S., Coutinho, J. A. P., & Freire, M. G. (2020) · Scientific Reports · doi:10.1038/s41598-020-71925-8 · Cited by 18
Socioeconomic differences in prostate cancer treatment: A systematic review and meta-analysis
Gallagher, B. D. T., Coughlin, E. C., Nair‐Shalliker, V., McCaffery, K. J., & Smith, D. P. (2022) · Cancer Epidemiology · doi:10.1016/j.canep.2022.102164 · Cited by 18
Mortality and biochemical recurrence after surgery, brachytherapy, or external radiotherapy for localized prostate cancer: a 10-year follow-up cohort study
Suárez, J. F., Zamora, V., Garín, O., Gutiérrez, C., Pont, À., Pardo, Y., Goñi, A., Mariño, A., Hervas, A., Herruzo, I., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16395-w · Cited by 18
AR activates YAP/TAZ differentially in prostate cancer
Salem, O., Jia, S., Qian, B., & Hansen, C. G. (2023) · Life Science Alliance · doi:10.26508/lsa.202201620 · Cited by 18
NCAPG2 promotes prostate cancer malignancy and stemness via STAT3/c-MYC signaling
Zhang, E., Chen, Z., Liu, W., Lin, L., Wu, L., Guan, J., Wang, J., Kong, C., Bi, J., & Zhang, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04834-9 · Cited by 18
A piece in prostate cancer puzzle: Future perspective of novel molecular signatures
Nassir, A. M. (2020) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2020.02.003 · Cited by 18
Prostate Cancer Treatment and Work: A Scoping Review
Ko, W. F. Y., Oliffe, J. L., & Bottorff, J. L. (2020) · American Journal of Men s Health · doi:10.1177/1557988320979257 · Cited by 17
Patient participation in treatment decision-making of prostate cancer: a qualitative study
Pan, S., Mao, J., Wang, L., Dai, Y., & Wang, W. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-021-06753-1 · Cited by 17
A Web-Based Intervention to Reduce Distress After Prostate Cancer Treatment: Development and Feasibility of the Getting Down to Coping Program in Two Different Clinical Settings
Cockle‐Hearne, J., Barnett, D., Hicks, J. A., Simpson, M. F., White, I. D., & Faithfull, S. (2018) · JMIR Cancer · doi:10.2196/cancer.8918 · Cited by 17
Five‐year trends of bone scan and prostate‐specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre
Haran, C., McBean, R. S., Parsons, R., & Wong, D. (2019) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.12885 · Cited by 17
Men’s sexual help-seeking and care needs after radical prostatectomy or other non-hormonal, active prostate cancer treatments
Hyde, M. K., Opozda, M. J., Laurie, K., Vincent, A. D., Oliffe, J. L., Nelson, C. J., Dunn, J. C., Chung, E., Gillman, M., Manecksha, R. P., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05775-5 · Cited by 19
Identification of a DNA Repair Gene Signature and Establishment of a Prognostic Nomogram Predicting Biochemical-Recurrence-Free Survival of Prostate Cancer
Long, G., Ouyang, W., Zhang, Y., Sun, G., Gan, J., Hu, Z., & Li, H. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.608369 · Cited by 16
Stimulating effect of palmitate and insulin on cell migration and proliferation in PNT1A and PC3 prostate cells: Counteracting role of metformin
Landim, B. C., de Jesus, M. M., Bosque, B. P., Zanon, R. G., da Silva, C. V., Góes, R. M., & Ribeiro, D. L. (2018) · The Prostate · doi:10.1002/pros.23517 · Cited by 16
Evidence-based approach to active surveillance of prostate cancer
Witherspoon, L., Breau, R. H., & Lavallée, L. T. (2019) · World Journal of Urology · doi:10.1007/s00345-019-02662-5 · Cited by 17
Sandwich-type electrochemical immunosensor based on nitrogen-doped porous carbon and nanoporous trimetallic nanozyme (PdAgCu) for determination of prostate specific antigen
Shang, Q. H., Dong, H. Y., Liu, S., Jiang, F., Li, Y., Wang, S., Liu, Q., Li, Y., & Tang, F. (2022) · Microchimica Acta · doi:10.1007/s00604-022-05458-4 · Cited by 16
The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network
Banna, G. L., Basso, U., Giunta, E. F., Fratino, L., Rebuzzi, S. E., Buti, S., Maruzzo, M., Giorgi, U. D., Murianni, V., Cinausero, M., et al. (2022) · Current Oncology · doi:10.3390/curroncol29100612 · Cited by 16
Development and internal validation of PI-RADs v2-based model for clinically significant prostate cancer
Zhang, Y., Zeng, N., Zhu, Y. C., Huang, Y. X. R., Guo, Q., & Tian, Y. (2018) · World Journal of Surgical Oncology · doi:10.1186/s12957-018-1367-9 · Cited by 16
Dietary inflammatory index is associated with increased risk for prostate cancer among Vietnamese men
Hoang, D. V., Shivappa, N., Pham, N. M., Hébert, J. R., Binns, C. W., & Lee, A. H. (2019) · Nutrition · doi:10.1016/j.nut.2018.12.012 · Cited by 17
Screening for prostate cancer: are organized screening programs necessary?
Roobol, M. J. (2018) · Translational Andrology and Urology · doi:10.21037/tau.2017.12.10 · Cited by 16
Immunoregulation effects of TIM-3 on tumors
Sheng, C. C., & Han, F. (2018) · Neoplasma · doi:10.4149/neo_2018_180610n385 · Cited by 15
Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness
Lang, R. E., Rolny, V., Leinenbach, A., Karl, J., Lange, M. S.-D., Kobold, U., Schrader, M. G., Krause, H., Mueller, M., & Vogeser, M. (2019) · Tumor Biology · doi:10.1177/1010428319827223 · Cited by 16
Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis
Chys, B., Devos, G., Everaerts, W., Albersen, M., Moris, L., Claessens, F., Meerleer, G. D., Haustermans, K. M., Briganti, A., Chłosta, P. L., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00246 · Cited by 16
Enhanced inhibition of tumor growth using TRAIL-overexpressing adipose-derived stem cells in combination with the chemotherapeutic agent CPT-11 in castration-resistant prostate cancer
Kim, J. H., Oh, E., Han, Y. S., Lee, S. H., & Song, Y. S. (2020) · Prostate International · doi:10.1016/j.prnil.2020.07.002 · Cited by 15
Determination of miRNA expression profile in patients with prostate cancer and benign prostate hyperplasia
Sancer, O., Koşar, P. A., Tepebaşı, M. Y., Ergün, O., DEMİR, M., & Koşar, A. (2022) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.55730/1300-0144.5374 · Cited by 15
Epidemiology of Urologic Cancer in Korea: Nationwide Trends in the Last 2 Decades
Han, S. H., & Yuk, H. D. (2023) · Journal of Urologic Oncology · doi:10.22465/juo.234600080004 · Cited by 15
An ecological momentary assessment of self-management in prostate cancer survivors
Paterson, C. C. (2019) · Journal of Cancer Survivorship · doi:10.1007/s11764-019-00758-w · Cited by 15
Safety of testosterone therapy in men with prostate cancer
Morgentaler, A., & Caliber, M. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1666103 · Cited by 15
Pelvic Floor Muscle Training in Radical Prostatectomy and Recent Understanding of the Male Continence Mechanism: A Review
Sayner, A. M., & Nahon, I. (2020) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2020.151050 · Cited by 15
Two novel peptides derived from Sinonovacula constricta inhibit the proliferation and induce apoptosis of human prostate cancer cells
Huang, F., Ding, G., Yang, Z., & Yu, F. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7418 · Cited by 14
Identification of SPOP related metabolic pathways in prostate cancer
Yan, M., Qi, H., Li, J., Ye, G., Shao, Y., Li, T., Liu, J., Piao, H., & Xu, G. (2017) · Oncotarget · doi:10.18632/oncotarget.21460 · Cited by 14
Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?
Leiris, N. D., Leenhardt, J., Boussat, B., Montemagno, C., Seiller, A., Sy, O. P., Roux, J., Laramas, M., Verry, C., Iriart, C., et al. (2020) · Cancer Imaging · doi:10.1186/s40644-020-00333-y · Cited by 15
Sociodemographic index and global trends in prostate cancer: 1990–2017
Launer, B. M., & Lloyd, G. L. (2021) · The Prostate · doi:10.1002/pros.24178 · Cited by 15
Cancer Statistics over Time in Northwestern São Paulo State, Brazil: Incidence and Mortality
da Costa, A. M., Hernandes, I. C. P., Weiderpass, E., Soerjomataram, I., & Fregnani, J. H. T. G. (2022) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-21-0842 · Cited by 14
PLGA nanomedical consignation: A novel approach for the management of prostate cancer
Dongsar, T. S., Dongsar, T. T., Gupta, G., Alsayari, A., Wahab, S., & Kesharwani, P. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.123808 · Cited by 14
Contemporary Epstein Criteria with Biopsy-Naïve Multiparametric Magnetic Resonance Imaging to Prevent Incorrect Assignment to Active Surveillance in the PI-RADS Version 2.0 Era
Fan, Y., Zhai, L., Meng, Y., Chen, Y., Sun, S.-S., Wang, H. H., Hu, S., Shen, Q., Liu, Y., Li, D., et al. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6720-2 · Cited by 13
Self-citation

Authors: Wong, M. C. S., Goggins, W. B., Wang, H. H. X., Fung, F. D. H., Leung, C., Wong, S. Y. S., Ng, C. F., & Sung, J. J. Y.
Affiliations: Prince of Wales Hospital (CN)
Chinese University of Hong Kong (HK)
Corresponding author: Sung, Joseph J.Y.
ORCID: Wong, Martin C.S.
Goggins, William B.
Leung, Colette
Wong, Samuel Y.S.
Ng, Chi Fai
Sung, Joseph J.Y.
Venue: European Urology
Publisher: Elsevier BV
Published: 2016-11
Volume: 70
Issue: 5
Pages: 862-874
ISSN: 0302-2838 (ISSN-L)
DOI: 10.1016/j.eururo.2016.05.043
OpenAlex: W2415076046
Cited by: 513
References: 28
Citations by year: 2026: 21 · 2025: 29 · 2024: 46 · 2023: 46 · 2022: 44 · 2021: 66 · 2020: 66 · 2019: 90 · 2018: 55 · 2017: 46 · 2016: 3
FWCI: 34.88
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: European Urology (publishedVersion)
PubMed (publishedVersion)
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
Topics: Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Keywords: prostate cancer, cancer incidence, cancer mortality, temporal trends, socio-economic development, Human Development Index, gross domestic product, global variation, age-standardized rates, cancer registry
MeSH terms: Adult, Age Factors, Aged, Developing Countries, Female, Humans, Male, Middle Aged, Mortality, Prostatic Neoplasms, Socioeconomic Factors, Global Health, World Health Organization, Incidence, Databases, Factual, Developed Countries

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks